triple agonist glp 1 Beyond GLP-1: Retatrutide's triple-agonist mechanism (GLP-1, GIP, glucagon) is redefining metabolic health. Phase 2 data shows ~24% weight loss—surpassing semaglutide & tirzepatide. Evidence-based protocols demand nutrition support alongside prescribing Retatrutide 40mg | Triple GIP/GLP-1/Glucagon
Description
In comparison to placebo, liraglutide treatment reduced the prevalence of NAFLD by two-thirds, the amount of fat in the liver by 44%, visceral adipose tissue by 18%, and body weight by 5.2 kg (5.6%) (199)
In the Brain: GLP-1 decreases appetite, increase satiety and energy production
Expanded FDA Indications In 2024/2025 The potential uses for GLP-1s are expanding rapidly, moving well beyond their original purpose of diabetes management
Do GLP-1 medications affect contraception
